image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IL
$ 1.56
5.41 %
$ 73.6 M
Market Cap
-3.63
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one INCR stock under the worst case scenario is HIDDEN Compared to the current market price of 1.56 USD, InterCure Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one INCR stock under the base case scenario is HIDDEN Compared to the current market price of 1.56 USD, InterCure Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one INCR stock under the best case scenario is HIDDEN Compared to the current market price of 1.56 USD, InterCure Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INCR

image
$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.215 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
239 M REVENUE
-32.82%
-67.2 M OPERATING INCOME
-61.69%
-72.8 M NET INCOME
-14.58%
-66.9 M OPERATING CASH FLOW
-24.79%
17.7 M INVESTING CASH FLOW
270.61%
26.5 M FINANCING CASH FLOW
131.92%
56.6 M REVENUE
0.00%
-38.9 M OPERATING INCOME
-0.00%
716 K NET INCOME
0.00%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet InterCure Ltd.
image
Current Assets 392 M
Cash & Short-Term Investments 78.7 M
Receivables 180 M
Other Current Assets 133 M
Non-Current Assets 371 M
Long-Term Investments 2.15 M
PP&E 105 M
Other Non-Current Assets 263 M
10.31 %23.67 %17.40 %13.80 %34.54 %Total Assets$762.6m
Current Liabilities 227 M
Accounts Payable 77.5 M
Short-Term Debt 74.2 M
Other Current Liabilities 75 M
Non-Current Liabilities 138 M
Long-Term Debt 137 M
Other Non-Current Liabilities 973 K
21.25 %20.34 %20.55 %37.59 %Total Liabilities$364.9m
EFFICIENCY
Earnings Waterfall InterCure Ltd.
image
Revenue 239 M
Cost Of Revenue 209 M
Gross Profit 30.2 M
Operating Expenses 97.4 M
Operating Income -67.2 M
Other Expenses 5.58 M
Net Income -72.8 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)239m(209m)30m(97m)(67m)(6m)(73m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
12.66% GROSS MARGIN
12.66%
-28.14% OPERATING MARGIN
-28.14%
-28.38% NET MARGIN
-28.38%
-17.08% ROE
-17.08%
-8.89% ROA
-8.89%
-9.18% ROIC
-9.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis InterCure Ltd.
image
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -72.8 M
Depreciation & Amortization 15.4 M
Capital Expenditures -4.38 M
Stock-Based Compensation 2.28 M
Change in Working Capital -9.19 M
Others 15.8 M
Free Cash Flow -71.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets InterCure Ltd.
image
INCR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership InterCure Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza.  InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility. prnewswire.com - 2 months ago
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak NEW YORK and HERZLIYA, Israel , Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. prnewswire.com - 4 months ago
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. prnewswire.com - 6 months ago
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates. benzinga.com - 9 months ago
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure  Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the six months ended June 30, 2024. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. globenewswire.com - 10 months ago
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies' branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across. businesswire.com - 10 months ago
InterCure: A Cannabis Industry Leader Still Flying Under The Radar InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken. seekingalpha.com - 1 year ago
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCu. businesswire.com - 1 year ago
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial Highlights and Milestones Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, a. businesswire.com - 1 year ago
InterCure: Bargain Israel Cannabis Play InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond. seekingalpha.com - 1 year ago
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the Canna. businesswire.com - 1 year ago
PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry. This legislative milestone, by removing cannabis from the 'narcotics act', is set to significantly ease the prescription process for medical cannabis, heralding profound implications for medical professionals, patients, and companies operating within th. businesswire.com - 1 year ago
8. Profile Summary

InterCure Ltd. INCR

image
COUNTRY IL
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 73.6 M
Dividend Yield 0.00%
Description InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
Contact 85 Medinat ha-Yehudim Street, Herzliya, 4676670 https://www.intercure.co
IPO Date Jan. 28, 2019
Employees 320
Officers Einat Zehavi Vice President of Sales Mr. Alexander Rabinovich Chief Executive Officer & Chairman Itai Kabiljo General Counsel Mr. Amos Cohen Chief Financial Officer